In a recent study, a truncating variant of RAD52 has been found to significantly reduce the breast cancer risk in BRCA2 mutation carriers, which supports a role for RAD52 as a genetic modifier of cancer predisposition associated with BRCA2 loss (Adamson et al., 2020). The gene discussed is BRCA2; the disease is cancer.